Adaptive Biotechnologies Corporation (ADPT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.3800 |
| Open | 4.3600 |
| Bid | 4.6600 x 1400 |
| Ask | 4.7300 x 800 |
| Day's Range | 4.2101 - 4.7700 |
| 52 Week Range | 2.6050 - 10.7900 |
| Volume | |
| Avg. Volume | 1,538,582 |
| Market Cap | 680.433M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3600 |
| Earnings Date | Feb 12, 2024 - Feb 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADPT
Related Research
- Adaptive Biotechnologies CorporAnalyst Report: Guardant Health, Inc.Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.RatingFair ValueEconomic Moat4 days agoMorningstar
Simply Wall St.Analysts Just Slashed Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) EPS Numbers
The analysts covering Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) delivered a dose of negativity to...
Insider MonkeyAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 EPS, expectations were $-0.32. Operator: Thank you for standing by. At this time, I would like to welcome everyone to today’s Adaptive Biotechnologies 2023 Third Quarter Earnings Call. All lines have been […]
GlobeNewswireAdaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2023. “We have two compelling businesses in MRD and Immune Medicine, which continue to make significant progress in divergent ways,” said Chad Ro
